

2018 - 1

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

McClure Matthew W.¹, Berliba Elina², Tsertsvadze Tengiz³, Streinu-Cercel Adrian⁴, Vijgen Leen⁵, Astruc Beatrice⁶, Patat Alain A.⁶, Westland Christopher E.¹, Chanda Sushmita¹, Zhang Qingling¹, Kakuda Thomas¹, Vuong Jennifer¹, Khorlin Nick¹, Beigelman Leonid N.¹, Blatt Lawrence Mitchell¹, Fry John¹

¹ Alios BioPharma, Inc.,

² "Nicolae Testemițanu" State University of Medicine and Pharmacy,

³ AIDS and Clinical Immunology Research Center of Georgia,

⁴ University of Medicine and Pharmacy "Carol Davila", Bucharest,

⁵ Janssen Research & Development BE, Beerse,

⁶ Biotrial

PLoS ONE

Nr. 10(13) / 2018 / ISSN 1932-6203

Disponibil online 5 December, 2018. Descarcări-0. Vizualizări-692

2013 - 1

ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity in treatment-naïve GT1 chronic hepatitis C patients

Marcellin Patrick¹, Popa Sergiu², Berliba Elina², Boyer Nathalie¹, Streinu-Cercel Anca³, Tong Myron⁴, Kauffman Robert⁵, Koziel Margaret⁵, Chanda Sushmita⁶, Zhang Qingling⁶, Westland Christopher E.⁶, Beigelman Leonid N.⁶, Blatt Lawrence Mitchell⁶, Fry John⁶

¹ Hopital Beaujon,

² F.C.E. ARENSIA Exploratory Medicine,

³ "Professor Dr. Matei Balș" National Institute of Infectious Diseases,

⁴ Huntington Medical Research Institutes, Pasadena, CA,

⁵ Vertex Pharmaceuticals Inc, Cambridge, MA ,

⁶ Alios BioPharma, Inc.

Hepatology International

Nr. S1(7) / 2013 / ISSN 1936-0533 / ISSNe 1936-0541

Disponibil online 17 December, 2021. Descarcări-0. Vizualizări-570
